Skip to content
Precision for Medicine
Contact Us
24

Experts in the Intricacies of Cell Therapy Development

End-to-end experience in delivering a broad range of cell therapies Contact us

Precision was born from a desire to support innovators in precision medicine. Your cell therapy project will be enriched by our collective experience in cell therapy development.

40. Human cells under a microscope

Helping innovators deliver on the promise of cell therapy

Cell therapy development is at the forefront of advanced therapeutic modalities, especially in oncology research, but the intricacies can complicate the development process.

Precision’s experience developing a broad range of cell therapies, including CAR T cells, stem cells, autologous and allogeneic products, and tumor-infiltrating lymphocytes, gives us insight into the challenges of cell therapy as a whole, as well as how development of each of these cell types differ.

We are working with leaders in cell therapy innovation and take pride in the FDA approvals we’ve supported.

25 countries with cell therapy trials
11 worldwide labs with PBMC processing
20 cell therapy trials in the last 5 years

A precise and integrated approach to cell therapy development.

Specialized capabilities and proven expertise in cell therapy development helps compress timelines and find efficiencies in every stage. When your team is collaborating under one global roof, you find ways to work smarter and bring novel therapies to market faster.

  • Explore
    clinicalTrialDesign_background
    clinical-laboratory-support

    Clinical Trial Design

    • Full service CRO for global trials
    • Patient recruitment and enrollment: specialization in rare disease
    • Expertise with current regulatory environment
    • Operational excellence in cell therapy study conduct
    Explore
    clinical-laboratory-support

    Clinical Trial Design

    • Full service CRO for global trials
    • Patient recruitment and enrollment: specialization in rare disease
    • Expertise with current regulatory environment
    • Operational excellence in cell therapy study conduct
    Explore
  • Explore
    specialty Labs

    Specialty Lab Services

    • Immune Monitoring
    • Bioanalysis
    • Genomics
    • IHC/mIF and Pathology
    • Liquid Biopsy
    Explore

    Specialty Lab Services

    • Immune Monitoring
    • Bioanalysis
    • Genomics
    • IHC/mIF and Pathology
    • Liquid Biopsy
    Explore
  • Explore
    biospecimen
    biospecimens

    Biospecimens

    • PBMCs—healthy and disease state
    • NGS characterized biospecimens
    • Tissues

    Explore
    biospecimens

    Biospecimens

    • PBMCs—healthy and disease state
    • NGS characterized biospecimens
    • Tissues

    Explore
  • Explore
    PBMC
    sample-processing

    PBMC & Sample Processing

    Sample processing with expertise in PBMC isolations from labs across 5 continents

    Explore
    sample-processing

    PBMC & Sample Processing

    Sample processing with expertise in PBMC isolations from labs across 5 continents

    Explore
  • Explore
    Researchers works in chemistry laboratory
    commercialization

    CDx Development & Commercialization

    • Biomarker discovery and assay development
    • Preclinical planning and strategy
    • Assay development into single-site PMA CDx with full regulatory and market support
    Explore
    commercialization

    CDx Development & Commercialization

    • Biomarker discovery and assay development
    • Preclinical planning and strategy
    • Assay development into single-site PMA CDx with full regulatory and market support
    Explore
spanningthescpectrum

Expertise in cell therapy trials

For cell therapy trials there is a keen demand for high-quality, efficient, well-run studies that enable teams to move rapidly in an iterative development cycle. Our experienced team recognizes the nuances involved and prepares trial strategies that address safety, site selection, training, patient recruitment and logistics. 

Explore

Scientific capabilities support cell therapies in the lab

Precision supports cell therapy development with a complete suite of biomarker assay services including assay development, validation and implementation to support every phase of your cell therapy project. Our team includes thought leaders in immunogenicity testing that are helping shape the regulatory landscape.

Explore

Top leadership ratings for a CRO in the ISR Report 2024

  • CROLeadership2024Compatability
  • CROLeadership2024Capabilities
  • CROLeadership2024Reliability
  • CROLeadership2024Quality
  • CROLeadership2024Expertise

Our latest insights on cell therapy development

Discover
Read: Case Study: Conducting Autologous Cell Therapy Research Across 3 Continents with Zero Sample Loss Case Study: Conducting Autologous Cell Therapy Research Across 3 Continents with Zero Sample Loss

Clinical Trials - Oncology - Cell Therapies

Case Study: Conducting Autologous Cell Therapy Research Across 3 Continents with Zero Sample Loss

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=164725548848, hs_child_table_id=0, hs_updated_at=1754641451547, hs_published_at=1786473638412, description=Alexis Hobbins-White is an accomplished leader who plays a pivotal role in navigating the complex landscape of global oncology and rare disease-focused clinical trials. With a career spanning over 15 years in the clinical trials industry, Alexis brings a wealth of experience across multiple therapeutic areas, showcasing her proficiency in diverse aspects of operational strategy. She specializes in early phase adaptive studies, particularly in immuno-oncology and advanced therapeutics. She has an MSc in Neuroscience and an MA in Biotechnology Law and Ethics., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Alexis-Hobbins.png',altText='Alexis-Hobbins',fileId=194096322982}, linkedin=https://www.linkedin.com/in/alexis-hobbins-white-400a1720/, lastname=Hobbins-White, hs_initial_published_at=1713362276020, hs_created_by_user_id=5166971, hs_created_at=1713361952861, hs_is_edited=false, hs_deleted_at=0, name=Alexis, job=Senior Director, Operational Strategy , slug=alexis-hobbins-white, hs_updated_by_user_id=65712240}, second={}, third={}})
  • Alexis Hobbins-White avatar

    Alexis Hobbins-White
Discover
Read: FDA Approves Breakthrough Cell Therapy for Synovial Sarcoma FDA Approves Breakthrough Cell Therapy for Synovial Sarcoma

Oncology - Cell Therapies

FDA Approves Breakthrough Cell Therapy for Synovial Sarcoma

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778887, hs_child_table_id=0, hs_updated_at=1715690972359, hs_published_at=1786473638412, description=Andy Kinley, Ph.D. is Vice President of Innovation and Clinical Science at Precision for Medicine. He is a clinical researcher with over 25 years of combined experience leading basic and clinical research in oncology and hematology. His early scientific career focused on cancer cell signaling, setting a foundation to complement his clinical research roles in trial design and implementation of effective strategies for oncology clinical trials. Andy specializes in immuno-oncology trials (checkpoint inhibitors, T-cell agonists, bispecifics, cytokines, oncolytic viruses, neoantigen cancer vaccines), including autologous and allogeneic adoptive cell therapies (CAR-T, TCR, TIL, NK cells). Today, Andy identifies and implements innovative tools, datasets, and services that can impact clinical trial execution including quality, patient diversity, site identification, and trial timelines., avatar=Image{width=720,height=829,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/AndyKinley_headshot.png',altText='AndyKinley_headshot',fileId=167369936018}, linkedin=https://www.linkedin.com/in/andy-kinley-phd-5759551, hs_name=, hs_path=, lastname=Kinley, hs_initial_published_at=1775839468505, hs_created_at=1709645745118, hs_is_edited=false, hs_deleted_at=0, name=Andy, job=, slug=andy-kinley, email=, hs_updated_by_user_id=65712240}, second={}, third={}})
  • Andy Kinley avatar

    Andy Kinley
Discover
Read: Clinical Trial Trends: Cell Therapy Clinical Trial Landscape: Cell Therapies

Clinical Trials - Cell Therapies

Clinical Trial Trends: Cell Therapy

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=164725548848, hs_child_table_id=0, hs_updated_at=1754641451547, hs_published_at=1786473638412, description=Alexis Hobbins-White is an accomplished leader who plays a pivotal role in navigating the complex landscape of global oncology and rare disease-focused clinical trials. With a career spanning over 15 years in the clinical trials industry, Alexis brings a wealth of experience across multiple therapeutic areas, showcasing her proficiency in diverse aspects of operational strategy. She specializes in early phase adaptive studies, particularly in immuno-oncology and advanced therapeutics. She has an MSc in Neuroscience and an MA in Biotechnology Law and Ethics., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Alexis-Hobbins.png',altText='Alexis-Hobbins',fileId=194096322982}, linkedin=https://www.linkedin.com/in/alexis-hobbins-white-400a1720/, lastname=Hobbins-White, hs_initial_published_at=1713362276020, hs_created_by_user_id=5166971, hs_created_at=1713361952861, hs_is_edited=false, hs_deleted_at=0, name=Alexis, job=Senior Director, Operational Strategy , slug=alexis-hobbins-white, hs_updated_by_user_id=65712240}, second={}, third={}})
  • Alexis Hobbins-White avatar

    Alexis Hobbins-White
Discover